Transgene presents new clinical and immunogenicity data for TG4050 that confirm the significant potential of this individualized immunotherapy:
o In all evaluable patients, target neoantigens could be identified; TG4050 induced specific T cell immune responses against several patient-specific tumor mutations.
o Early signs of clinical activity were observed in several patients treated with the neoantigenic vaccine, characterized by durable and promising antitumor activity.
o Production times and delivery of individualized clinical batches are compatible with the schedules provided by the clinical trial protocols.
…/…